{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.343","value":"1.65"},{"groupId":"OG001","spread":"0.0801","value":"0.111"},{"groupId":"OG002","spread":"0.0942","value":"0.164"},{"groupId":"OG003","spread":"0.363","value":"1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.09","value":"17.6"},{"groupId":"OG001","spread":"3.07","value":"6.09"},{"groupId":"OG002","spread":"2.91","value":"13.7"},{"groupId":"OG003","spread":"4.00","value":"31.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"title":"Day 85"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"N is the number of participants with available data at this time point.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 160 mg of enzalutamide orally once a day during double blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer (up to 29.4 months). Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer (up to 54.3 months).","id":"OG000","title":"Enzalutamide"},{"description":"Inactive metabolite","id":"OG001","title":"M1- Carboxylic Acid Metabolite"},{"description":"N-desmethyl enzalutamide (active metabolite)","id":"OG002","title":"M2- N-Desmethyl Enzalutamide"},{"description":"Active metabolite","id":"OG003","title":"Enzalutamide Plus M2"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetic Analysis Set (PKAS) population consisted of all participants who received at least 1 dose of study drug and who provided blood samples for drug concentrations at at least 1 time point.","reportingStatus":"POSTED","timeFrame":"From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85","title":"Concentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2","type":"SECONDARY","unitOfMeasure":"μg/mL"}